Exagen Inc. (XGN) Dividend History

Company News

• Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors

  If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

  Zacks Investment Research
• Exagen to Announce First Quarter 2024 Results on May 13, 2024

  CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT).

  GlobeNewswire Inc.
• BTIG Maintains Buy Rating for Exagen: Here's What You Need To Know

  BTIG has decided to maintain its Buy rating of Exagen (NASDAQ:XGN) and lower its price target from $6.00 to $5.00. Shares of Exagen are trading down 3.91% over the last 24 hours, at $2.21 per share. A move to $5.00 would account for a 126.24% increase from the current share price. About Exagen Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and ...Full story available on Benzinga.com

  Benzinga
• Exagen Inc. (XGN) Q2 2022 Earnings Call Transcript

  XGN earnings call for the period ending June 30, 2022.

  The Motley Fool